Ethris

This #NationalDoctorsDay, we extend our heartfelt thank you to the doctors that share our vision of advancing the development of innovative mRNA-based vaccines and therapies.

Our Business Development team is attending the #BIOEuropeSpring conference in Barcelona, Spain presented by @EBDGroup! We look forward to connecting with the biopharma community to discuss potential partnerships that will help us advance our pipeline. brnw.ch/21wHYlx

As we further advance our clinical efforts, we look forward to highlighting the pulmonary delivery capabilities of our lead product candidates. #LearnMore about the unmet medical need within our therapeutic program areas: brnw.ch/21wHHlz

Our goal is to develop therapeutics for the treatment of rare diseases such as Primary Ciliary Dyskinesia (PCD) and Pulmonary alveolar proteinosis (PAP). This #RareDiseaseDay and beyond, we’re proud to focus on helping those living with rare diseases we aim to treat.

#ICYMI, our study of ETH47 has advanced into the clinical phase. ETH47 was developed using Ethris’ Stabilized Non-Immunogenic mRNA (SNIM®RNA) platform. To learn more about our technology, see here: brnw.ch/21wGTCX

The Business of Biotech podcast featuring our CEO, Dr. Carsten Rudolph, is now available! Thank you to host Matthew Pillar for allowing us to expand on our mission. Listen now: brnw.ch/21wGGI2

Our CMO, Dr. Thomas Langenickel, presented a poster on our progress in #PrimaryCiliaryDyskinesia at @PCDFoundation's On the Move International Scientific Conference in Puerto Rico last week. We're honored to be part of advancing treatment for those in the #PCD community. #OTM2024

Our Chief Technology Officer, Dr. Christian Plank, will be speaking at TIDES Asia in Kyoto, Japan, on March 21 at 8:15. His session will focus on the use of mRNA technology in our lead candidate for preventing and treating viral infections. Learn more: brnw.ch/21wGAko

Our CMO, Dr. Thomas Langenickel, spoke with @GlobalGenes on the power behind our inhaled #mRNA product candidate for Primary Ciliary Dyskinesia (PCD), and how it may help patients breathe easier. Thank you to @dslevine for help telling our story. Listen: brnw.ch/21wGydB

#ICYMI, our CEO, Dr. Carsten Rudolph, Estelle Beguin, PhD, and Nigel Horscroft presented at the 3rd Annual #mRNA-Based Therapeutics Summit. Each gave a unique look into our pipeline & research. We look forward to more in 2024! #WorldRNASeries

Here is a sneak peak of our CEO, Dr. Carsten Rudolph, speaking with Matthew Pillar, host of the Business of Biotech podcast at #JPM2024. Stay tuned for the release of the episode in the coming months, which will discuss our recent developments in mRNA technology and more.

Our leadership team will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit. Join us January 23-25 in Berlin to learn about our pipeline. Register now: brnw.ch/21wG9DK

#DYK that our first product candidate to move to clinic, ETH47, is a differentiated approach to potentially treat and prevent severe disease following respiratory viral infections, especially in patients at risk? Read more: brnw.ch/21wG2fP

We're thrilled to announce our participation in the prestigious @JPMorgan Healthcare Conference this year! Meet with us to learn how we’re navigating the future of #mRNA and uncover groundbreaking innovations. #JPM24 #JPM2024

Our team has been traveling the world in 2023, attending some of the most influential conferences and events in the #biotech industry to discuss our mRNA and LNP technology platforms. We are excited about what's in store for the #NewYear! Learn more: brnw.ch/21wFEUw

Our CEO, Carsten Rudolph, speaks with Advancing RNA on upcoming advancements in #RNA technology. The conversation reveals that there is a lot to look forward to in the #NewYear, including our #ClinicalTrial. Read the feature: brnw.ch/21wFvKg

From all of us at Ethris, #HappyHolidays! We had a wonderful time celebrating with the team at our holiday party. Thank you all for the support in further developing our pipeline – we couldn’t do it without those who believe in our mission to deliver the future of #RNAMedicine.

We are thrilled to share a major milestone: The first participant has been dosed in our Phase I #ClinicalTrial for the first-in-class ETH47. We look forward to seeing how this study can fulfill the unmet need in addressing respiratory viral infections. brnw.ch/21wFpIp

Our CEO, Dr. Carsten Rudolph, is featured in this @GoHealio publication about the potential behind ETH47, an inhaled mRNA-based therapy for respiratory infections. Read the article: healio.com/news/pulmonology/…

In this month’s issue of Life Science Leader, our CEO Carsten Rudolph discusses the future of RNA medicine with other leaders, emphasizing the importance of “clinical proof of concept.” Read the issue: brnw.ch/21wEWMx